SAN FRANCISCO, Might 04, 2020 (GLOBE NEWSWIRE) — Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology firm discovering and growing novel small molecule therapeutics to deal with unmet wants in autoimmunity and most cancers, right this moment introduced the appointment of Noreen R. Henig, MD as its Chief Medical Officer. As an integral member of the Firm’s Govt Management staff, Dr. Henig will oversee all facets of the Firm’s scientific improvement, regulatory and medical affairs.
“Noreen brings together with her a depth and breadth of experience in scientific follow, translational science, scientific improvement, and medical affairs, and we’re thrilled to welcome her to the Kezar staff,” mentioned John Fowler, Kezar’s Chief Govt Officer. “Her confirmed management abilities, deep understanding of immunology and uncommon illnesses, and profound appreciation of the affected person voice will make a big affect, and I sit up for working in partnership together with her as we proceed to advance our novel therapies for a variety of autoimmune illnesses and cancers.”
Noreen Roth Henig, M.D. is a seasoned chief whose profession spans scientific follow, educational medication, translational science, scientific improvement, medical and regulatory affairs. She at present serves on the Board of Avidity Biosciences and most not too long ago served as Chief Medical Officer of Breath Therapeutics, which was acquired by Zambon SpA in 2019. As CMO, Dr. Henig constructed and led the scientific staff and was chargeable for all improvement actions together with scientific and non-clinical science, scientific operations, regulatory, venture administration, and medical affairs. Previous to becoming a member of Breath, Dr. Henig was Chief Medical Officer at ProQR Therapeutics the place she introduced two distinctive RNA oligonucleotides by early scientific trials in uncommon illnesses. Earlier than ProQR, Dr. Henig spent 2008 by 2014 at Gilead Sciences the place she held roles with rising accountability, together with constructing and main a world medical affairs group, strategic improvement of scientific trials Part 2-4, regulatory technique, company improvement, management of key alliances and industrial technique. Previous to becoming a member of business, Dr. Henig spent almost 10 years in management roles inside educational medication at Stanford College and California Pacific Medical Middle. She is a board-certified doctor in Pulmonary, Essential Care and board eligible in Allergy and Immunology. Dr. Henig acquired her B.A. from Yale College and her M.D. from Albert Einstein School of Drugs of Yeshiva College in 1991 with a distinction in immunology. She educated in Inside Drugs at College of California, San Francisco and in Pulmonary/Essential Care and Allergy/Immunology at College of Washington, Seattle.
“I’m excited to hitch Kezar at such an essential time within the firm’s progress,” mentioned Dr. Henig. “Kezar’s scientific excellence in protein homeostasis through protein degradation and secretion presents super alternative to create elegant therapies for these residing with severe and sometimes debilitating illnesses. It is going to be a pleasure to work alongside Kezar’s proficient and dynamic staff to comprehend our full potential by combining science with progressive approaches to improvement and affected person engagement.”
About Kezar Life Sciences
Based mostly in South San Francisco, Kezar Life Sciences is a clinical-stage biotechnology firm dedicated to revolutionizing therapies for sufferers with autoimmune illnesses and most cancers. Kezar is translating its progressive analysis on the immunoproteasome and protein secretion pathways to advance novel therapeutic approaches. KZR-616, a first-in-class selective immunoproteasome inhibitor, is being evaluated in extreme and underserved autoimmune illnesses. Moreover, Kezar has nominated KZR-261 as its first scientific candidate for the remedy of most cancers from its protein secretion program and is present process IND-enabling actions for this system. For extra data, go to www.kezarlifesciences.com.
CONTACT:
Celia Economides
SVP, Technique & Exterior Affairs
ceconomides@kezarbio.com
